Reference edition checked November 5, 2026 (ET). Reporting feeds update independently; reference facts retain their stated dates.
An AI system’s ability to produce a convincing answer is not proof it improves a real-world service. Deployment evidence depends on the industry, the workflow, the people affected and the outcome being measured. This guide follows AI applications across healthcare, finance, manufacturing, education, transportation, agriculture, retail, legal work and scientific research. It is a framework for interpreting reported uses, not a certification or a directory of approved products.
Healthcare and regulated uses
The FDA’s AI-enabled medical device list identifies devices authorized for marketing in the United States and links to relevant database entries. The agency explicitly says the list is not comprehensive. Authorization concerns a device and its intended use; it should not be extended to every feature, model or possible clinical setting. A laboratory result or a company demo is not itself marketing authorization.
For a clinical claim, establish the patient population, the study design, the comparison and the measured outcome. Distinguish diagnostic accuracy from patient benefit and from reduced workload. Human oversight and integration into the clinical workflow matter. Existing TBR reporting on AI diagnosis is a starting point for examining the source study, not a substitute for medical advice.
Business, education and professional work
Financial, legal and educational uses can involve consequential decisions and sensitive data. A successful pilot should identify the task, the number and type of users, the review process and whether errors were counted. Automating one step does not establish end-to-end reliability. Output that appears fluent may still need factual and legal checking.
The NIST risk framework provides a voluntary way to organize trustworthiness concerns across the lifecycle. The EU AI Act resource describes a risk-based legal framework including sensitive use cases. Their roles differ: a risk-management framework is not a universal legal approval, and a legal classification is not a measured productivity outcome. Readers should check the applicable sector and jurisdiction.
Physical systems and scientific workflows
Manufacturing, transportation, farming and retail operations involve environments that can differ from the development dataset. A computer-vision test may not capture lighting, weather, machine variation or unusual events in deployment. A robotics demonstration can be constrained to a prepared environment. Read the robotics guide for the distinction between perception, planning and safe physical action.
Scientific applications likewise need validation suited to the domain. A predicted structure, material or experimental result can guide investigation without being a completed physical demonstration. Our research guide follows papers and reproducibility. Across all these sectors, look for evidence of improvements in quality, reliability, cost or time, along with who bears the consequences when the system fails. This initial applications page links verified resources and reporting rather than inventing adoption percentages for industries with no comparable audited dataset.
Questions to ask before drawing a conclusion
- What exact workflow and intended use are being evaluated?
- Is the evidence a pilot, controlled study, production outcome or vendor demonstration?
- What comparison group and quality measure were used?
- How are errors, human review and affected people accounted for?
- Does any regulatory authorization cover the exact product and use being described?
Record the deployment setting
A reusable application record should name the organization, workflow, geography, evaluation dates and source. Preserve whether the system is experimental, piloted or used in production, along with the outcome measured and the amount of human review. A vendor customer quotation may identify a use case without establishing a causal improvement. This page does not convert examples from one organization into an industry-wide adoption rate or presume that the same product is appropriate everywhere.
Related TBR reporting
- Microsoft AI Diagnosis Tool Outscores Generalist Doctors in Science Study 2026-10-23
- Ledgebrook Raises $200 Million as Allianz X Backs Boston AI Insurance Platform 2026-10-18
- Apple Opens Siri AI to Third-Party Apps, Letting Developers Plug In Actions and Multi-Step “App Skills” 2026-11-03
- Schools That Switch Off Google’s AI Will Lose Google Search Too, Starting in Early 2027 2026-11-04
- Flagship Merges Cellarity, Etiome and Empress Into AI Biotech Etcelera 2026-10-29